SUBSCRIBE
SUBSCRIBE
News   Drug Development

First Patient Treated in BioInvent’s Phase I Study of the Drug Candidate BI-505 to Treat Multiple Myeloma

January 4, 2010 | 
1 min read
Bookmark and Share

LUND, Sweden--(BUSINESS WIRE)--BioInvent International AB (STO:BINV) announced today that the first patient has been treated in an open, dose-escalation phase I study of the company’s antibody BI-505 for patients with advanced multiple myeloma.
Clinical research Phase 1 Europe
MORE ON THIS TOPIC
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Duchenne muscular dystrophy
Dyne Plans Post-Prasad FDA Run as Duchenne Exon Skipper Sustains Benefit in Long Term Data
March 10, 2026
 · 
3 min read
 · 
Tristan Manalac
Concept World kidney day, handcraft paper blue kidneys and stethoscope on yellow background. Copy space. Banner.
IgA nephropathy
Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA
March 10, 2026
 · 
2 min read
 · 
Tristan Manalac
Flat 3d isometric business people came from different way but have same target. Business team and target concept.
Insights
Single Pivotal Trials Demand Stronger Data and Risk Strategies
March 10, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Businessman looks at the rugged road
Obesity
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
March 9, 2026
 · 
2 min read
 · 
Heather McKenzie